The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157029 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Luis Bettio und 12 weiteren Autor:innen. Beteiligte Einrichtung: Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada. Hauptthemen laut MEDLINE: Anticonvulsants, Seizures. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The assessment of the efficacy of antiseizure medications (ASMs) in animal models of acute seizures has played a critical role in these drugs’ success in clinical trials for human epilepsy. One of the most widely used animal models for this purpose is the maximal electroshock seizure (MES) model. While there are numerous published reports on the efficacy of conventional ASMs in MES models, there is a need to expand the understanding on the brain concentrations that are needed to achieve optimal levels of efficacy in this model. We assessed the pharmacokinetic/pharmacodynamic (PK/PD) profiles of six ASMs, namely carbamazepine (CBZ), phenytoin (PHT), valproic acid (VPA), lacosamide (LSM), cenobamate (CNB), and retigabine (RTG), using MES models in mice and rats. EC50 values for plasma and the brain were generally higher in mice than rats, with fold differences ranging from 1.3- to 8.6-fold for plasma and from 1.2- to 11.5-fold for brain. Phenytoin showed the largest interspecies divergence. These results suggest that rats may exhibit greater sensitivity to seizure protection in the MES model, likely reflecting species differences in metabolism and brain penetration. These findings highlight the value of considering concentration–response variations and species-specific differences when assessing the efficacy of both conventional ASMs and novel compounds exhibiting anticonvulsant activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.
ORCID-Profile: Stephanie Lee, Richard Dean, James P Johnson, Nina Weishaupt
Zitieren
APA
Bettio, L., Bankar, G., Dubé, C. M., Nelkenbrecher, K., Filipovic, M., Singh, S., DeBoer, G., Lee, S., Lindgren, A., Sojo, L., Dean, R., Johnson, J. P., & Weishaupt, N. (2025). The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157029
Vancouver
Bettio L, Bankar G, Dubé CM, Nelkenbrecher K, Filipovic M, Singh S, et al. The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157029
BibTeX
@article{Bettio2025,
author = {Bettio, Luis and Bankar, Girish and Dubé, Celine M and Nelkenbrecher, Karen and Filipovic, Maja and Singh, Sarbjot and DeBoer, Gina and Lee, Stephanie and Lindgren, Andrea and Sojo, Luis and Dean, Richard and Johnson, James P and Weishaupt, Nina},
title = {The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157029}
}
EUVIMED